NX-5948 and NX-2127, in two oral presentations and one poster at the 66th American Society of Hematology Annual Meeting and Exposition being held December 7-10, 2024, in San Diego, CA.

About NX-2127: NX-2127 is an investigational, orally bioavailable degrader of BTK and cereblon neosubstrates Ikaros (IKZF1) and Aiolos (IKZF3). NX-2127 is currently being evaluated in a Phase 1a/b ...

Additional information on the Phase 1a/b clinical trial can be accessed at www.clinicaltrials.gov (NCT05131022). About NX-2127: NX-2127 is an investigational, orally bioavailable degrader of BTK and ...

NX-5948 and NX-2127, in two oral presentations and one poster at the 66th American Society of Hematology Annual Meeting and Exposition being held December 7-10, 2024, in San Diego, CA. About NX-5948: ...

Additional information on the Phase 1a/b clinical trial can be accessed at (NCT05131022 ). About NX-2127: NX-2127 is an investigational, orally bioavailable degrader of BTK and cereblon ...

Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies. Its drug candidate from E3 ...

Nx is a build system, optimized for monorepos, with plugins for popular frameworks and tools and advanced CI capabilities including caching and distribution.

Additionally, they reinitiated enrollment for NX-2127 in a phase 1a/b trial in oncology and presented preclinical data on degrader-antibody conjugates (DACs). In terms of financials, collaboration ...